{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:40:58Z","timestamp":1775522458567,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgar.2021.03.023","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:02:28Z","timestamp":1618963348000},"page":"264-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens"],"prefix":"10.1016","volume":"25","author":[{"given":"Ang\u00e9lica","family":"Terashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Canales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Maco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.03.023_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-030-18616-6_4","article-title":"Fascioliasis","volume":"1154","author":"Mas-Coma","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jgar.2021.03.023_bib0002","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/trstmh\/trz093","article-title":"Triclabendazole in the treatment of human fascioliasis: a review","volume":"113","author":"Gandhi","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.03.023_bib0003","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/vr.105209","article-title":"Lack of efficacy of triclabendazole against Fasciola hepatica is present on sheep farms in three regions of England, and Wales","volume":"184","author":"Kamaludeen","year":"2019","journal-title":"Vet Rec"},{"key":"10.1016\/j.jgar.2021.03.023_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.vetpar.2015.02.014","article-title":"High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia","volume":"209","author":"Elliott","year":"2015","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.jgar.2021.03.023_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.4067\/S0034-98872014001000014","article-title":"Resistant human fascioliasis: report of four patients [in Spanish]","volume":"142","author":"Gil","year":"2014","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.jgar.2021.03.023_bib0006","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3201\/eid1806.120302","article-title":"Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands","volume":"18","author":"Winkelhagen","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.023_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004361","article-title":"Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series","volume":"10","author":"Cabada","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.03.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02373-18","article-title":"Screening the pathogen box for identification of new chemical agents with anti-Fasciola hepatica activity","volume":"63","author":"Machicado","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.03.023_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.actatropica.2011.07.002","article-title":"Hyperendemic human fascioliasis in Andean valleys: an altitudinal transect analysis in children of Cajamarca Province","volume":"120","author":"Gonz\u00e1lez","year":"2011","journal-title":"Peru. Acta Trop"},{"key":"10.1016\/j.jgar.2021.03.023_bib0010","first-page":"389","article-title":"Fasciola hepatica infection in Peru: an emergent disease [in Spanish]","volume":"27","author":"Marcos","year":"2007","journal-title":"Rev Gastroenterol Peru"},{"key":"10.1016\/j.jgar.2021.03.023_bib0011","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0037-8682-0148-2015","article-title":"Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children","volume":"48","author":"Maco","year":"2015","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.jgar.2021.03.023_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.vetpar.2013.01.001","article-title":"Resistance of Fasciola hepatica against triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep","volume":"195","author":"Ortiz","year":"2013","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.jgar.2021.03.023_bib0013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/QCO.0b013e32830f9818","article-title":"Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis","volume":"21","author":"Marcos","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jgar.2021.03.023_bib0014","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4269\/ajtmh.2008.78.222","article-title":"Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis","volume":"78","author":"Marcos","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.03.023_bib0015","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/1756-0500-5-691","article-title":"Sporadic incidence of fascioliasis detected during hepatobiliary procedures: a study of 18 patients from Sulaimaniyah Governorate","volume":"5","author":"Hawramy","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jgar.2021.03.023_bib0016","doi-asserted-by":"crossref","first-page":"e1285","DOI":"10.1371\/journal.pntd.0001285","article-title":"Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials","volume":"5","author":"Keiser","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.03.023_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4269\/ajtmh.2012.11-0476","article-title":"Cysticercosis Working Group in Peru. Efficacy of a single oral dose of oxfendazole against Fasciola hepatica in naturally infected sheep","volume":"86","author":"Gomez-Puerta","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.03.023_bib0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1365-2036.2003.01419.x","article-title":"Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru","volume":"17","author":"Favennec","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2021.03.023_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007779","article-title":"Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt","volume":"13","author":"Ramadan","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.03.023_bib0020","first-page":"79","article-title":"A short note on praziquantel in human fascioliasis","volume":"89","author":"Farag","year":"1986","journal-title":"J Trop Med Hyg"},{"key":"10.1016\/j.jgar.2021.03.023_bib0021","series-title":"Norma T\u00e9cnica de Salud para la Vigilancia, Prevenci\u00f3n y Control de la Fasciolosis Humana en el Per\u00fa [Technical Health Standard for the Surveillance, Prevention and Control of Human Fasciolosis in Peru]","year":"2019"},{"key":"10.1016\/j.jgar.2021.03.023_bib0022","unstructured":"US Food and Drug Administration (FDA). EGATEN\u2122 (triclabendazole) tablets, for oral use. Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208711Orig1s000Lbl.pdf [accessed 31 January 2021]."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:54Z","timestamp":1761991134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":22,"alternative-id":["S2213716521000904"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.023","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observational study on the effectiveness and safety of multiple regimens of triclabendazole in human fascioliasis after failure to standard-of-care regimens","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}